Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage

Impact · against what's priced in

Cogent Biosciences is well-positioned for commercialization due to robust pivotal data for bezuclastinib and a strong cash runway through 2028. The three regulatory filings and high liquidity significantly de-risk the path to revenue generation.

COGT+0.70

No priced-in read yet

In context

The company has submitted three regulatory filings for bezuclastinib backed by robust pivotal trial data and maintains $866.4 million in cash to fund operations through 2028.

Read from the article alone

• biotech
• COGT
• cash runway
• clinical trials
• drug pipeline
• fda filing
• oncology

Search tags